Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ImmunoGen Inc.

    NASDAQ: IMGN · Real-Time Price · USD
    31.23
    0.00 (0.00%)
    At close: Feb 09, 2024, 9:58 PM

    ImmunoGen Statistics

    Share Statistics

    ImmunoGen has 279.35M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 279.35M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 247.85M

    Failed to Deliver (FTD) Shares

    n/a
    		 132

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 20.61M, so 7.38% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 20.61M

    Short % of Shares Out

    n/a
    		 7.38%

    Short % of Float

    n/a
    		 7.4%

    Short Ratio (days to cover)

    n/a
    		 5

    Valuation Ratios

    The PE ratio is -5.64 and the forward PE ratio is null. ImmunoGen's PEG ratio is 0.

    PE Ratio

    n/a
    		 -5.64

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 11.55

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 8.06

    P/FCF Ratio

    n/a
    		 -5.44

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    ImmunoGen has an Enterprise Value (EV) of 996.61M.

    EV / Sales

    n/a
    		 9.16

    EV / EBITDA

    n/a
    		 -4.58

    EV / EBIT

    n/a
    		 -4.34

    EV / FCF

    n/a
    		 -4.31

    Financial Position

    The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.1.

    Current Ratio

    n/a
    		 2.26

    Quick Ratio

    n/a
    		 2.5

    Debt / Equity

    n/a
    		 0.1

    Debt / EBITDA

    n/a
    		 -0.07

    Debt / FCF

    n/a
    		 -0.07

    Interest Coverage

    n/a
    		 -53.04

    Financial Efficiency

    Return on Equity is -143.06% and Return on Invested Capital is -129.83%.

    Return on Equity

    n/a
    		 -143.06%

    Return on Assets

    n/a
    		 -63.89%

    Return on Invested Capital

    n/a
    		 -129.83%

    Revenue Per Employee

    n/a
    		 $392,714.8

    Profits Per Employee

    n/a
    		 $-804,797.83

    Employee Count

    n/a
    		 277

    Asset Turnover

    n/a
    		 0.31

    Inventory Turnover

    n/a
    		 -0.01

    Taxes

    Income Tax

    n/a
    		 1.22M

    Effective Tax Rate

    n/a
    		 -0.55%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 1.17, so ImmunoGen's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.17

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 29.69

    200-Day Moving Average

    n/a
    		 19.27

    Relative Strength Index (RSI)

    n/a
    		 82.52

    Average Volume (20 Days)

    n/a
    		 8,287,745

    Income Statement

    In the last 12 months, ImmunoGen had revenue of 108.78M and earned -222.93M in profits. Earnings per share was -0.88.

    Revenue

    n/a
    		 108.78M

    Gross Profit

    n/a
    		 108.61M

    Operating Income

    n/a
    		 -220.89M

    Net Income

    n/a
    		 -222.93M

    EBITDA

    n/a
    		 -217.55M

    EBIT

    n/a
    		 -217.55M

    Earnings Per Share (EPS)

    n/a
    		 -0.88
    Full Income Statement

    Balance Sheet

    The company has 275.14M in cash and 15.24M in debt, giving a net cash position of 259.89M.

    Cash & Cash Equivalents

    n/a
    		 275.14M

    Total Debt

    n/a
    		 15.24M

    Net Cash

    n/a
    		 259.89M

    Retained Earnings

    n/a
    		 -1.69B

    Total Assets

    n/a
    		 822.1M

    Working Capital

    n/a
    		 601.57M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -229.8M and capital expenditures -1.36M, giving a free cash flow of -231.17M.

    Operating Cash Flow

    n/a
    		 -229.8M

    Capital Expenditures

    n/a
    		 -1.36M

    Free Cash Flow

    n/a
    		 -231.17M

    FCF Per Share

    n/a
    		 -0.91
    Full Cash Flow Statement

    Margins

    Gross margin is 99.84%, with operating and profit margins of -203.06% and -204.93%.

    Gross Margin

    n/a
    		 99.84%

    Operating Margin

    n/a
    		 -203.06%

    Pretax Margin

    n/a
    		 -203.81%

    Profit Margin

    n/a
    		 -204.93%

    EBITDA Margin

    n/a
    		 -199.98%

    EBIT Margin

    n/a
    		 -203.06%

    FCF Margin

    n/a
    		 -212.5%

    Dividends & Yields

    IMGN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -17.74%

    FCF Yield

    n/a
    		 -18.4%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for IMGN.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 18.12

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist